Merck Backs Off Revolution After Failing To Agree on Price: WSJ

Why It Matters

The collapse reshapes the biotech M&A landscape, affecting valuation benchmarks and Merck’s strategy to replenish its oncology pipeline before Keytruda’s patent cliff.

Key Takeaways

• Merck and Revolution failed to agree on price.
• Proposed valuation ranged between $28 billion and $32 billion.
• Daraxonrasib shows strong ORR in pancreatic cancer trials.
• Merck seeks new assets before Keytruda patent expiry.
• AbbVie denied interest despite earlier $20 billion rumor.

Pulse Analysis

The stalled Merck‑Revolution deal underscores how price expectations can derail even the most promising biotech acquisitions. While Merck boasts a robust balance sheet, its willingness to spend multi‑tens of billions hinges on securing assets that can quickly replace revenue from Keytruda, whose exclusivity is set to expire. The inability to bridge a $4 billion valuation gap signals heightened caution among large pharma, especially as they weigh the risk‑adjusted returns of early‑stage oncology programs against cash‑intensive buyouts.

Daraxonrasib, Revolution’s oral selective RAS inhibitor, has emerged as a rare bright spot in a crowded pipeline. Phase I data revealed a 29% confirmed objective response rate in second‑line pancreatic cancer and a 47% response in first‑line settings, outcomes that are compelling for a disease with limited treatment options. The FDA Commissioner’s National Priority Voucher further accelerates its path to market, potentially compressing a typical 12‑month review into a single‑digit timeframe. Such attributes not only boost the drug’s intrinsic value but also make Revolution an attractive target for any company seeking a foothold in RAS‑driven oncology.

For Merck, the missed acquisition forces a strategic pivot. The company may explore alternative partnerships, licensing deals, or internal development to fill the impending pipeline gap. Meanwhile, other suitors like AbbVie could re‑emerge, especially if Revolution’s upcoming 2026 readouts confirm the early efficacy signals. Investors will watch the stock closely; a successful deal could lift Merck’s growth outlook, while continued uncertainty may pressure its share price amid broader market skepticism about high‑priced biotech deals.